What is Amolyt Pharma?
Founded in 2014 and headquartered in France, Amolyt Pharma operates at the intersection of innovation and clinical necessity. The company specializes in the development of therapeutic peptides designed to treat rare endocrine and metabolic conditions, a sector characterized by high barriers to entry and significant unmet medical needs. By focusing on precision medicine and novel drug delivery mechanisms, Amolyt Pharma has established itself as a critical player in the biotech ecosystem, bridging the gap between academic research and commercial-scale clinical application. Its market position is bolstered by a robust intellectual property portfolio and a strategic focus on high-potential therapeutic targets.
How much funding has Amolyt Pharma raised?
Amolyt Pharma has raised a total of $316.5M across 6 funding rounds:
Private Equity
$6.6M
Unspecified
$1.9M
Private Equity
$17.1M
Series A
$72.9M
Series B
$80M
Series C
$138M
Private Equity (2014): $6.6M with participation from Bpifrance and Octalfa
Unspecified (2015): $1.9M led by Sham Innovation Santu00e9, Rhu00f4ne-Alpes Cru00e9ation, and Octalfa
Private Equity (2016): $17.1M, investors not publicly disclosed
Series A (2019): $72.9M featuring Turenne Capital, Life Sciences Partners, Pontifax, Orbimed, TAB Consulting, Kurma Partners, Sham Innovation Santé, Novo Ventures, Innobio 2, Crédit Agricole Création, and Partners Innovation Fund
Series B (2021): $80M backed by Sectoral Asset Management, Andera Partners, Novo Holdings, ATEM Capital, and Kurma Partners
Series C (2023): $138M with participation from Novo Holdings, Tekla Healthcare Opportunities, ICG, Sofinnova Partners, Kurma Partners, CTI Life Sciences Fund, and Andera Partners
Key Investors in Amolyt Pharma
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in life sciences.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Andera Partners
Andera Partners is a major player in private company investments in France and internationally, with a dedicated life sciences team managing significant capital in the biotech sector.
What's next for Amolyt Pharma?
Following the successful completion of its latest funding round, Amolyt Pharma is poised to transition into a more mature phase of clinical operations. The strategic deployment of this capital will likely focus on accelerating late-stage clinical trials, expanding its research infrastructure, and potentially exploring new therapeutic indications within the endocrine space. As the company continues to scale, the focus will remain on achieving key regulatory milestones and demonstrating the efficacy of its lead candidates. With the backing of top-tier life sciences investors, Amolyt Pharma is strategically aligned to navigate the complexities of the global biotech market, aiming to deliver transformative outcomes for patients suffering from rare metabolic diseases.
See full Amolyt Pharma company page
